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A META-ANALYSIS OF THREE-DAY AZITHROMYCIN THERAPY
VERSUS LONGER COURSES OF COMPARATOR ANTIBIOTICS
IN ACUTE SINUSITIS
Harnett J, Enuha S, Xuan J, Cappelleri J
Pﬁzer, Inc, New York, NY, USA
OBJECTIVES: The objective of this meta-analysis is to review
published clinical trials evaluating the relative efﬁcacy of a three-
day regimen of azithromycin versus longer courses of compara-
tor antibiotics. METHODS: A literature search using Medline
and Embase identiﬁed randomized controlled trials that were
published in the English language and evaluated the efﬁcacy of
a 3-day regimen of azithromycin versus 10 days of active com-
parators in adult patients with acute sinusitis. Pooled odds ratios
were calculated for clinical success (cure + improvement) at the
end of therapy (range: day 10–15) using the Mantel-Haenszel
ﬁxed-effect and random-effect models. RESULTS: Among the 7
eligible studies with 1721 patients, the estimated overall success
rate at the end of therapy (random effect odds ratio: 1.13, 95%
CI: 0.79–1.62) was in favor of azithromycin, although this dif-
ference did not reach statistical signiﬁcance. There were no dif-
ferences in ﬁndings between the ﬁxed- and random-effect
models. CONCLUSIONS: A 3-day regimen of azithromycin has
at least comparable efﬁcacy to longer courses of comparator
antibiotics.
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TAMPON-RELATED TOXIC SHOCK SYNDROME (TSS)
CONTINUES TO PEAK AMONG ADOLESCENT GIRLS: A
NATIONWIDE HOSPITAL STUDY
Bright R, Cope J
Food and Drug Administration, Rockville, MD, USA
Despite the removal of certain types of tampons from the market,
tampon-related TSS may still lead to lengthy hospitalization and
morbidity for adolescent girls. TSS may be confused with other
acute illnesses. OBJECTIVE: To investigate the national rates of
TSS hospitalizations among adolescent girls. METHODS: Data
from the Health care Cost and Utilization Project (HCUP), col-
lected by the US Agency for Health care Research and Quality,
were used for these analyses. The HCUP Nationwide Inpatient
Sample (NIS), years 1996–2001, was obtained for ages 10–19,
20–39, and 40–59. Tampon-related TSS was computed as the
age-speciﬁc rate in females minus the age-speciﬁc rate in males.
Weighted national estimates for each sex-speciﬁc age group were
calculated by month of the year and by year. The HCUP Kids’
Inpatient Database (KID), 1997, was divided into ages 0–4, 5–9,
10–14, and 15–18 years. Sex-speciﬁc age group compared
Numbers of TSS cases. RESULTS: The highest national annual
number of tampon-related TSS hospitalizations was for 10–19
year olds, averaging 197 during the years 1996–2001. By con-
trast, the national average annual number of TSS hospitalization
for boys age 10–19 was 76, of tampon-related TSS hospitaliza-
tions for 20–39 year old women was 278, and of tampon-related
TSS hospitalizations for 40–59 year old women was 94. TSS
death rates were lowest for teens. Teen girls demonstrated a
unique pattern of elevated rates during the school months. The
KID data showed that TSS peaked for girls age 15–18, who suf-
fered nearly half of all cases among girls. Below age 10 similar
numbers of TSS occurred for boys and girls. CONCLUSION:
Increased awareness of TSS and related conditions should be
further deﬁned for subpopulations of adolescent girls who may
be at higher risk.
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CHANGES IN HIV ANTIVIRAL PHENOTYPIC DRUG
RESISTANCE DURING THE HAART ERA
Hess GP, Nelson C, Seiders J
Surveillance Data, Plymouth Meeting, PA, USA
OBJECTIVE: Patients newly diagnosed with HIV infection are
treated initially with three-drug regimens, and many patients
have been treated with drugs from three different classes of
inhibitors. Optimization of treatment strategies has resulted in
improved survival, but resistance develops readily in many
patients, and correlates with availability of and exposure to anti-
retroviral therapy. We studied patient-level trends and variation
in phenotypic resistance at several times during the HAART era
in the four major U.S. census regions. METHODS: An auto-
mated percent sample of patient-level phenotypic resistance
testing data from Virologic Inc. was analyzed for July
20101–June 2003. Test results were assigned to zip codes, unique
synthetic markers were generated for each record, and protected
health information was deleted. 1) Data at the national level was
analyzed comparing the average rate of phenotypic resistance
seen for each antiviral class in July 2001–June 2002 compared
to July 2002–June 2003, and 2) for each US census region com-
pared to the US-wide average. Results were analyzed for statis-
tically signiﬁcant differences. RESULTS: There were 500,000 +
phenotypic drug resistance tests results in the combined study
period. 1) No signiﬁcant differences were seen in the average US-
wide phenotypic resistance by class for July 2002–June 2003
compared to July 2001–June 2002. 2) Signiﬁcant differences
were seen for patient level phenotypic resistance by class when
comparing various Regions to the US-wide average, and when
comparing regions to each other. CONCLUSION: While the
average phenotypic resistance to HIV antivirals by class
remained unchanged from the 12-month comparative periods,
signiﬁcant differences exist across Regions. Clinicians need to
consider Regional variation in susceptibility to HIV antivirals in
interpreting national ﬁndings and guidelines, and in patient-level
prescribing decisions.
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AN EVIDENCE BASED PROPOSAL TO MODIFY PRESCRIBING
PATTERNS: THE CASE OF METRONIDAZOL USED WHEN
INTESTINAL AMOEBIASIS IS SUSPECTED
Medecigo-Micete C, Garduno-Espinosa J, Constantino-Casas P,
Gomez-Delgado A, Munoz-Hernandez O
Mexican Institute for Social Security, Mexico City, Mexico
OBJECTIVES: To discuss the importance of published evidence
to modify prescribing behaviours and to describe the case of
metronidazol in suspected intestinal amoebiasis. METHODS: In
Mexico and developing countries intestinal, amoebiasis is over
diagnosed in acute diarrhoea (Entamoeba histolytica found only
in 2%) with the consequent over use of metronidazol (40–60%).
We reviewed 90,700 prescriptions during August 1999 in three
primary care facilities in Mexico City. A total of 1790 prescrip-
tions of oral metronidazol were found and 300 were randomly
chosen to review the medical charts (diagnosis and dosage char-
acteristics). Micro-costing was also performed using the prices
of the institution. RESULTS: Metronidazol was prescribed when
intestinal amoebiasis was suspected in 746 cases (83%). The pre-
scriptions did not follow the established criteria (WHO and
other authors) in 96% (n = 724). Metronidazol was prescribed
when there was diarrhoea with mucus and blood in 57% and in
unspeciﬁed data of “colitis” in 39%. Only in 8 cases asympto-
matic amoebiasis was diagnosed. Mean monthly cost per medical
ofﬁce of unjustiﬁed metronidazol prescription was $43.5
Mexican pesos (4 USD). The national annual projection of that
